Connect with us

Business

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 

Published

on

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 


The Omada Health logo is displayed on a smartphone screen.

Sopa Images | Lightrocket | Getty Images

Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications.

Omada plans to expand the offerings under its weight management program as its membership grows to more than 800,000.

The announcement comes as digital health companies increase their presence in the blockbuster market for GLP-1s to treat obesity, diabetes and other chronic conditions – a space that could be worth roughly $100 billion by the end of the decade, according to some analysts. Several digital health companies similarly offer prescriptions for GLP-1s, and the manufacturers of those drugs, Eli Lilly and Novo Nordisk, are taking steps to make their treatments more accessible while also developing new ones for patients.

“The announcement is in response to our belief that access to GLP-1s will grow pretty significantly over time,” Omada co-founder and CEO Sean Duffy said in an interview. He said Omada recognizes that the market will expand beyond GLP-1 injections to pills and other “next-generation” treatments that work in different ways, underscoring the need to help patients manage their medications. 

Programs from companies like Omada aim to support lifestyle and behavioral changes for patients on those drugs, offering nutrition guidance, education and a team of health coaches and exercise specialists, among other resources, that can help people stay on the drugs longer. But Omada is now tapping licensed providers trained in obesity care to prescribe medications and help patients manage the drugs. 

The new offering will allow the company to support patients as they receive a prescription and through the time they spend on a GLP-1. That kind of support is crucial, as GLP-1 injections can be complicated for patients to use properly and often come with gastrointestinal side effects that force some people to stop treatment.

“If you need to go up in dose, down in those, switch medications – you name it. We’ll be able to support you through this experience,” Duffy said.

Omada, which partners with national and regional health plans and employers, also said the new offering is an add-on for customers to better support their workers’ health needs while controlling costs and improving results from obesity treatments. 

Also on Thursday, Omada Health reported quarterly earnings for the second time since its initial public offering in June.

The company, founded in 2011, offers virtual care programs to support patients with chronic conditions such as prediabetes, diabetes and hypertension. Omada describes its approach as a “between-visit care model” that is complementary to the broader health-care ecosystem.



Source link

Business

‘Made strong entry’: Amit shah hails semiconductor sector’s growth despite being ‘bit late’; confident of ‘exports soon’ – The Times of India

Published

on

‘Made strong entry’: Amit shah hails semiconductor sector’s growth despite being ‘bit late’; confident of ‘exports soon’ – The Times of India


NEW DELHI: India would soon establish itself in the semiconductor industry by starting exports, even though it’s entry was late, said Union home minister Amit Shah.“We have made a strong entry into the semiconductor industry, although a bit late. In no time, we will not only become self-reliant in the semiconductor sector, but will also start exporting it,” he said, addressing the ‘Abhyudaya Madhya Pradesh Growth Summit’.Speaking at the summit, Shah highlighted Madhya Pradesh’s attractive geographical location and fertile land.He also inaugurated industrial projects worth Rs 2 lakh crore, on the occasion of former Prime Minister Atal Bihari Vajpayee‘s 101st birth anniversary. He remembered Vajpayee as “a great orator, a sensitive poet, a leader dedicated to public welfare and remained ‘ajatashatru’ (person without enemies) in politics.”He noted that even small investments in the state could yield substantial returns. He praised Madhya Pradesh’s transformation from a power-deficient state to one with surplus electricity. He also commended the state’s achievements in cleanliness, saying it has surpassed other states in this aspect.During the event, Shah also paid tributes to Pandit Madan Mohan Malviya on his birth anniversary and C Rajagopalachari on his death anniversary. The Growth Summit attracted 25,000 beneficiaries and thousands of entrepreneurs and investors. Officials confirmed that the industrial projects launched during the event will create 193,000 new jobs.Shah’s visit also included inaugurating the Gwalior Fair and dedicating the renovated Atal Museum to the public, further marking the celebrations of Vajpayee’s birth anniversary.



Source link

Continue Reading

Business

Planning Your Taxes For 2026? What Freelancers And Gig Workers Should Know

Published

on

Planning Your Taxes For 2026? What Freelancers And Gig Workers Should Know




Source link

Continue Reading

Business

SFIO probes IndusInd’s Rs 1,960 crore derivatives hole – The Times of India

Published

on

SFIO probes IndusInd’s Rs 1,960 crore derivatives hole – The Times of India


MUMBAI: Serious Fraud Investigation Office (SFIO) has opened a formal probe into IndusInd Bank after a Dec 23, 2025 letter triggered an investigation under the Companies Act, 2013, over accounting lapses tied to internal derivative trades.In a filing, the bank said SFIO, under the MCA, seeks information after the lender flagged on June 2 issues spanning internal derivatives, unsubstantiated “other assets/liabilities”, and microfinance interest/fee income. It disclosed the update on Dec 18, pledged full cooperation, and posted details on its website.Derivatives irregularities have hit P&L by about Rs 1,960 crore as of March 31, 2025, eroding reported net worth by roughly 2.3% as of Dec 2024. Earlier profits were overstated as notional gains flowed into P&L while losses sat parked as assets, inflating NII and earnings quality. The derivatives irregularities saw several members of the senior management stepping down with the board bringing in Rajiv Anand from Axis Bank to head the private lender.The bank recognised the losses, absorbed pain in its FY25 earnings which tipped the bank into a Q4 FY25 net loss after one-off write-offs/provisions. Capital/net worth took a 2–2.5% post-tax hit, trimming buffers and nudging growth appetite and capital pricing.The derivatives loss resulted in the shares of the bank sliding as investors reassessed earnings credibility and governance. The scrutiny also sharpened on the board/management/audit committees, intensifying regulatory pressure and SFIO oversight.



Source link

Continue Reading

Trending